The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.

ABSTRACT:

Purpose

Blocking the interaction between the programmed cell death (PD)-1 protein and one of its ligands, PD-L1, has been reported to have impressive antitumor responses. Therapeutics targeting this pathway are currently in clinical trials. Pembrolizumab and nivolumab are the first of this anti-PD-1 pathway family of checkpoint inhibitors to gain accelerated approval from the US Food and Drug Administration (FDA) for the treatment of ipilimumab-refractory melanoma. Nivolumab has been associated with improved overall survival compared with dacarbazine in patients with previously untreated wild-type serine/threonine-protein kinase B-raf proto-oncogene BRAF melanoma. Although the most mature data are in the treatment of melanoma, the FDA has granted approval of nivolumab for squamous

SUBMITTER: Mahoney KM 

PROVIDER: S-EPMC4497957 | biostudies-literature | 2015 Apr

REPOSITORIES: biostudies-literature